首页> 外文期刊>Journal of Clinical Pathology >Immunohistochemical analysis of desmoid tumours.
【24h】

Immunohistochemical analysis of desmoid tumours.

机译:胶质瘤的免疫组织化学分析。

获取原文
获取原文并翻译 | 示例
           

摘要

Background/AIMS: Although the standard treatment for desmoid tumours is complete surgical resection with wide margins, the optimal adjuvant treatment for recurrent or inoperable disease is unclear, often being based on sporadic immunohistochemical reports with a low number of cases. Therefore, a large immunohistochemical study was performed, to provide a theoretical basis for adjuvant treatment regimens.METHODS: One hundred and sixteen tissue samples from 80 patients (49 female, 31 male; mean age, 34 years; range, 0-83) with desmoid tumours (46 extra-abdominal, 21 abdominal, 13 intra-abdominal) were tested for oestrogen receptors alpha and beta, progesterone and androgen receptors, and somatostatin, in addition to HER2, cathepsin D, Ki-67, and c-KIT by immunohistochemistry.RESULTS: All samples were negative for oestrogen receptor alpha, HER2, and the progesterone receptor. Positive staining for the androgen receptor was found in six extra-abdominal cases. Staining for oestrogen receptor beta was positive in four extra-abdominal, two abdominal, and one intra-abdominal case. Staining for somatostatin was positive in six extra-abdominal, two abdominal, and one intra-abdominal case, and staining for cathepsin D was positive in all cases. Positive staining for Ki-67 was found in 14 extra-abdominal, three abdominal, and three intra-abdominal cases. C-KIT was detectable in one abdominal case only.CONCLUSIONS: The data from this immunohistochemical study show that the published effects of antioestrogens and imatinib mesylate in the treatment of aggressive fibromatoses may not be attributable to oestrogen receptor alpha or c-KIT expression.
机译:背景/目的:尽管针对类胶质瘤的标准治疗是大范围的完整手术切除,但对于复发性或无法手术的疾病,最佳的辅助治疗尚不清楚,这通常是基于零星的免疫组化报告,病例数很少。因此,进行了一项大规模的免疫组织化学研究,为辅助治疗方案提供了理论基础。方法:从80例患者中(女性49例,男性31例;平均年龄34岁;范围0-83),共116份组织样本。除HER2,组织蛋白酶D,Ki-67和c-KIT之外,还测试了类胶质瘤(46腹外,21腹内,13腹内)的雌激素受体α和β,孕激素和雄激素受体以及生长抑素。结果:所有样品的雌激素受体α,HER2和孕激素受体均为阴性。在六例腹部外病例中发现了雄激素受体的阳性染色。在4例腹外,2例腹内和1例腹腔内病例中,雌激素受体β染色阳性。腹部外,腹部两腹和腹部内六例的生长抑素染色均为阳性,所有情况下组织蛋白酶D染色均为阳性。在14例腹部外,3例腹腔和3例腹腔内病例中发现Ki-67阳性。结论:仅在一个腹部病例中可检测到C-KIT。结论:这项免疫组织化学研究的数据表明,抗雌激素和甲磺酸伊马替尼在已公布的侵袭性纤维瘤治疗中的作用可能与雌激素受体α或c-KIT表达无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号